What Is a Tetrazine Drug and How Does It Work?

A tetrazine drug is not a single medication you can pick up at a pharmacy. It is a class of experimental therapeutics built around a small nitrogen-rich ring molecule called a tetrazine, which reacts with a partner molecule inside the body through an extraordinarily fast and selective chemical reaction. The core idea is to split a treatment into two steps: first, deliver one half of the chemistry to a disease site (usually a tumor), then send the second half through the bloodstream, where it finds and clicks with the first half to release an active drug exactly where it is needed. The approach has reached early human trials for cancer, and researchers are also using the same chemistry for medical imaging and laboratory tools.

The Chemistry Behind the Click

Tetrazines are six-membered rings containing four nitrogen atoms. That unusual structure makes the ring electron-poor, which is the key to its reactivity. When a tetrazine meets a strained, electron-rich partner molecule, the two snap together in a reaction chemists call an inverse electron demand Diels-Alder cycloaddition. The most common partner is trans-cyclooctene (TCO), a ring-shaped hydrocarbon that carries internal strain like a compressed spring. When these two molecules collide, the tetrazine ring breaks open, nitrogen gas escapes as a harmless byproduct, and the two pieces fuse into a new, stable structure.

What makes this reaction remarkable for medicine is its speed and selectivity. Among all known click chemistry reactions, tetrazine-TCO ligations are the fastest, with rate constants spanning from about 1 to 1,000,000 per molar per second in water at room temperature.¹ That range is enormous, and the exact speed depends on how the tetrazine and its partner are designed. Electron-withdrawing groups on the tetrazine lower its energy frontier and make it hungrier for electron-rich partners, speeding up the reaction.² The reaction also proceeds cleanly in biological fluids without interfering with the body’s own chemistry, a property researchers call bioorthogonality.³

Bioorthogonality and Why It Matters for Drugs

Your body is a dense soup of proteins, sugars, fats, and small molecules, all constantly reacting with one another. Any chemistry you introduce for therapeutic purposes has to avoid getting tangled up in that biological machinery. Bioorthogonal reactions are specifically designed to use chemical groups that do not naturally exist in living systems, so the two partner molecules find each other and react without touching anything else.⁴ Tetrazines and TCO fit this criterion well. Neither molecule resembles anything the body normally produces, and their mutual attraction is so strong and specific that they react with each other far faster than they degrade or get sidetracked by biological molecules.

This selectivity opens up strategies that conventional drugs cannot achieve. A standard chemotherapy drug, for example, circulates through the entire body and damages healthy tissue along the way. A tetrazine-based approach can, in principle, confine the drug’s activity to a precise location by keeping the drug inactive until the click reaction switches it on.

The Two-Step Pretargeting Strategy

Most tetrazine-based therapies follow a pretargeting playbook with two distinct injections. In the first step, a targeting agent carrying one half of the click pair is delivered to the disease site. This could be an antibody engineered to seek out a tumor marker, or a biopolymer injected directly into a tumor. The targeting agent is decorated with TCO groups. Once it has had enough time to accumulate at the target (hours to days, depending on the agent), the second step follows: a tetrazine-bearing compound is injected intravenously. The tetrazine circulates through the bloodstream, and wherever it encounters TCO already parked at the tumor, the two click together.

What happens at that click depends on the application. In imaging, the click might trap a radioactive tracer at the tumor so a PET scanner can see it. In therapy, the click might uncage an active drug that was chemically locked in an inactive form. The beauty of the system is that the potent payload only becomes active or localized at the site where both halves meet.

Prodrug Activation Through Click-to-Release

One of the most promising uses of tetrazine chemistry in medicine is prodrug activation. A prodrug is a medication that has been chemically modified so it is harmless while circulating but can be converted back into the active drug at the right time and place. Tetrazines can trigger this conversion with high efficiency and excellent biocompatibility.⁵

In a particularly creative demonstration, researchers designed a system where both halves of the click pair were themselves prodrugs. A tetrazine prodrug reacted with a vinyl-modified version of camptothecin, an anticancer compound. When the two clicked together, the reaction simultaneously released two different active agents: camptothecin itself and a separate molecule that inhibits a cancer-promoting microRNA. The reaction achieved over 85% conversion, and the dual release created a wider therapeutic window than either drug alone.⁶

Another research group showed that tetrazine labels placed on cancer cell surfaces could locally activate TCO-caged prodrugs and release the active drug directly at the tumor, achieving effective and safer cancer therapy compared to systemic delivery.⁷ The specificity here is striking: the drug is assembled, in a sense, at the very surface of the cancer cell rather than being released broadly into a tissue.

SQ3370 and the First Human Trials

The most advanced tetrazine-based therapy to reach patients is SQ3370, developed by Shasqi. It uses a biopolymer gel (called SQL70) injected directly into a tumor, loaded with chemical handles that can click with a modified version of doxorubicin (called SQP33) delivered intravenously. When SQP33 reaches the biopolymer in the tumor, the click reaction rapidly releases full-strength doxorubicin at very high local concentrations while keeping systemic exposure low.

In a Phase 1 dose-escalation trial enrolling 38 patients with advanced solid tumors, SQ3370 was given at doses ranging from about 0.4 to 15 times the standard doxorubicin dose. No protocol-defined dose-limiting toxicities were reported, and myelosuppression (a common and serious side effect of conventional doxorubicin) was mild and manageable. The 12-times dose was chosen for further study.⁸ That is a striking safety profile: patients received 15 times the normal dose of one of the most cardiotoxic chemotherapy drugs in existence, and the treatment remained tolerable.

A Phase 2a portion then enrolled 14 patients with soft tissue sarcoma at the 12-times dose. The disease control rate was about 71%, and immune profiling revealed expansion and activation of cancer-killing CD8+ T cells both in tumors and systemically. However, the objective response rate was roughly 14%, and because this did not exceed the prespecified threshold compared to standard doxorubicin, the study was terminated.⁹ The trial demonstrated that click chemistry can work inside human tumors, that the drug release was real and dose-dependent, and that the safety advantage was genuine. But it also illustrated that proof of chemistry does not automatically translate into better tumor shrinkage, at least not in a small, heavily pretreated population.

Pretargeted Imaging With Tetrazines

Drug therapy is only one side of the tetrazine story. The same click chemistry is being used to improve medical imaging, particularly PET scans. The problem with using antibodies to deliver radioactive tracers for PET is timing: antibodies take days to accumulate at a tumor, but most useful PET isotopes decay within hours. You cannot wait two days for your antibody to arrive if your tracer has a half-life of 110 minutes.

Pretargeted PET solves this mismatch. An antibody carrying a TCO group is injected first and given time to reach its target. Days later, a small, fast-clearing tetrazine labeled with fluorine-18 is injected. The tetrazine races through the body, clicks with any TCO it finds at the tumor, and gets trapped there just in time for the PET scan. This approach was first demonstrated in an ovarian cancer mouse model using a trastuzumab-tetrazine conjugate.¹⁰

Researchers have since expanded the approach to other targets. In a study monitoring PD-L1 expression (a checkpoint protein that helps tumors evade the immune system), a pretargeted strategy using atezolizumab-TCO and a fluorine-18-labeled tetrazine clearly outlined tumors in mice, achieving a tumor-to-muscle signal ratio of about 5.3, well above the roughly 2.4 seen in controls.¹¹ And in Alzheimer’s disease research, pretargeted PET with a TCO-modified antibody fragment and a fluorine-18 tetrazine revealed amyloid-beta plaques in the brains of mice modeling the disease, with higher signals in Alzheimer’s-prone brain regions like the hippocampus and thalamus compared to healthy controls.¹²

Fluorescence and Turn-On Probes

Beyond PET, tetrazines have a useful quirk for fluorescence imaging: many tetrazine-dye combinations are dark until the click reaction occurs. The tetrazine quenches the fluorescence of an attached dye through an energy-transfer mechanism, so the conjugate is essentially invisible. When the tetrazine reacts with its partner and the ring breaks apart, the quenching disappears and fluorescence switches on. Some newer probes achieve a turn-on ratio of up to 582-fold, meaning the signal after clicking is nearly 600 times brighter than before.¹³

This turn-on property is valuable because it dramatically reduces background noise. In conventional fluorescence imaging, unreacted dye floating around produces a hazy glow that obscures the signal you actually want to see. With tetrazine turn-on probes, only the dye molecules that have clicked with their targets light up. Researchers have used this approach to image individual receptors on living cell surfaces at super-resolution, including tumor necrosis factor receptors and kainate receptors involved in brain signaling.¹⁴ Earlier work had already shown that tetrazine-conjugated near-infrared fluorescent dyes could selectively label antibody-targeted cancer cells in the presence of serum, validating the approach for live-cell studies.¹⁵

The Reactivity-Stability Trade-Off

If faster-clicking tetrazines are better for medicine, why not just make the fastest one possible? The catch is that the same chemical features that make a tetrazine highly reactive also tend to make it unstable in biological fluids. A tetrazine loaded with electron-withdrawing groups clicks blazingly fast but may degrade before it ever reaches its target. This reactivity-stability trade-off has been one of the central engineering challenges in the field.¹⁶

Recent work has found ways to cheat this trade-off. One approach uses substituents that increase the tetrazine’s internal strain (making it more reactive) without pulling electrons away from the ring (which would reduce stability). A team showed that certain non-electron-withdrawing groups significantly boosted reaction speed while maintaining high stability in biological conditions.¹⁶ Another group developed tetrazines with hydroxyl or amido groups positioned near the reaction site, achieving payload release yields of 96% with tetrazines that were 18 times more reactive than previous designs.¹⁷

Stability against the body’s own reducing agents is another concern. Glutathione, a molecule found at high concentrations inside cells, can degrade certain tetrazines within hours. However, newer tetrazine designs have shown much better resistance: some peptide-conjugated tetrazines retained 85% to 96% of their integrity after 12 hours of exposure to glutathione levels mimicking the inside of a cell.¹⁸

Getting Tetrazines Where They Need to Go

For pretargeted approaches to work, the tetrazine probe must reach its target quickly, click efficiently, and then clear from the rest of the body so it does not generate false signals or off-target effects. Small-molecule tetrazines generally clear fast through the kidneys, which is ideal for imaging applications where you want leftover probe gone before you take the scan. In mice, low-molecular-weight tetrazine probes labeled with carbon-11 showed even biodistribution, good metabolic stability, and rapid excretion.¹⁹

Getting tetrazines into the brain is harder. The blood-brain barrier blocks most molecules from entering the central nervous system. A systematic evaluation of tetrazine tracers found that most did not cross this barrier, but at least one fluorine-18-labeled tetrazine showed brain penetration in mice, opening the door for neurological applications like the Alzheimer’s imaging work described earlier.²⁰ For tumor-targeted delivery, a tetrazine probe linked to a peptide and a radioactive iodine label showed prolonged retention in ovarian tumors with rapid clearance from the kidneys, a pharmacokinetic profile well suited for both imaging and potential radiotherapy.²¹

Tetrazine Chemistry in Biomaterials

Not all tetrazine applications involve injecting the molecule into a patient. The same click chemistry is being used to build medical materials like hydrogels, the squishy, water-rich scaffolds used in tissue engineering and wound healing. By attaching tetrazine and norbornene groups to alginate (a natural polymer from seaweed), researchers created hydrogels that crosslink through click chemistry under gentle, cell-friendly conditions. Living cells encapsulated within these gels survived the crosslinking process undamaged, making the material suitable for delivering cells or bioactive molecules to a wound or defect site.²² Traditional hydrogel crosslinking often requires UV light or chemical initiators that can harm cells, so the tetrazine approach solves a real practical problem.

Where the Field Stands

Tetrazine-based medicine is still early-stage by any honest assessment. The SQ3370 trial proved the chemistry works in humans, but the clinical efficacy bar was not met, and the program’s future course is uncertain. All other tetrazine applications remain preclinical, with the imaging and prodrug activation work confined to animal models. Designing tetrazines that are simultaneously reactive enough, stable enough, and pharmacokinetically well-behaved enough for routine clinical use remains a genuine chemical engineering puzzle, though the recent breakthroughs in decoupling reactivity from instability are encouraging. The sulfonation of hydroxyl-bearing tetrazines, for instance, has enabled complete prodrug release within minutes by fine-tuning the acidity of key functional groups.²³ Advances like these keep expanding the design space, giving chemists more knobs to turn as they try to engineer the ideal tetrazine for each medical application.